29th Congress of the European Society of Gene & Cell Therapy – ESGCT 2022 Oct 11 - Oct 14, 2022 Supporting Materials Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up 651 KB Engineering of Factor IX-secreting B cells using ZF-Nuclease / AAV6 editing technology in a GMP-compatible medium 1 MB
Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up 651 KB
Engineering of Factor IX-secreting B cells using ZF-Nuclease / AAV6 editing technology in a GMP-compatible medium 1 MB